Skip to main content

Research

The Centre for Applied Urological Research is actively involved in many clinical trials; Both investigator-driven in-house studies and large multi-institutional trials.

Current clinical trials include studies related to:

  • Bladder Cancer
  • Prostate Cancer
  • Interstitial Cystitis/ Bladder Pain Syndrome
  • Incontinence/ reUTI
  • Chronic Prostatitis
  • Kidney Stones

Dr. David Berman - Director, Queen's Cancer Research Institute

  • Evaluates novel biomarkers for therapeutics in Bladder and Prostate cancer

Dr. Charles Graham – Principal Investigator, CBG Division

  • Investigates the metastatic behaviour and resistance to therapy in Bladder cancer

Dr. Madhuri Koti - Principal Investigator, CBG Division

  • Investigates the role of anti-tumour immunity in therapeutic response for Prostate and Bladder cancer

Dr. Christopher Mueller - Principal Investigator, CBG Division

  • Evaluates novel biomarkers for disease progression in Prostate cancer

Dr.  Parvin Mousavi – Professor, Queen’s Computing

  • Computer-aided diagnosis and interventions for cancer detection
  • RADICAL PC Investigators. Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. J Urol. 2020.
  • Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020.
  • A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. J Clin Med. 2019 .
  • Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.  J Urol. 2018.
  • Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. J Urol. 2018.
  • Mirabegron as adjuvant treatment for patients with interstitial cystitis/bladder pain syndrome. CUAJ. 2018.
  • Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017.
  • Depression Associated with Use of 5-Alpha Reductase Inhibitors Compared to Use of Alpha Blockers for Benign Prostatic Hyperplasia: Population-based Study using the Clinical Practice Research Datalink.  Pharmacotherapy, 2017.
  • Risk of Gynecomastia and Breast Cancer Associated with Use of 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia.  Clinical Epidemiology, 2017. 
  • Progression from high grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, Soy and selenium. J Clin Onc. 2011.